



Test Definition: BRBPS

Broad Range Bacterial PCR and Sequencing,
Varies

Overview

Useful For

Detecting and identifying bacteria (including mycobacteria) from normally sterile sources, including synovial fluid; body fluids such as pleural, peritoneal, pericardial, and cerebrospinal fluid; and both fresh and formalin-fixed paraffin-embedded tissues

This test is **not recommended** as a test of cure because nucleic acids may persist for long periods of time after successful treatment.

Reflex Tests

Test Id	Reporting Name	Available Separately	Always Performed
ISNGS	Ident by Next Generation Sequencing	No, (Bill Only)	No
SPID2	Specimen Identification by PCR	No, (Bill Only)	No
CSFME	Meningitis Encephalitis Panel, PCR	Yes	No
JIP	Joint Infect Panel PCR, Synovial FI	Yes	No

Testing Algorithm

If polymerase chain reaction (PCR) test results are negative, no next-generation sequencing is performed.

If PCR testing is positive, next-generation sequencing is performed.

The following algorithms are available:

[-Infective Endocarditis: Diagnostic Testing for Identification of Microbiological Etiology](#)

[-Meningitis/Encephalitis Panel Algorithm](#)

Special Instructions

- [Infective Endocarditis: Diagnostic Testing for Identification of Microbiological Etiology](#)
- [Meningitis/Encephalitis Panel Algorithm](#)

Highlights

This test is used for detection and identification of bacteria (including mycobacteria) in normally sterile specimens.

This test is optimal for situations in which bacteria (including mycobacteria) are visualized in the specimen, but other laboratory methods have failed to yield a diagnosis.

Method Name

Polymerase Chain Reaction (PCR) followed by Next-Generation Sequencing

NY State Available

Yes

Specimen**Specimen Type**

Varies

Necessary Information**Specimen source is required.****Specimen Required**

Fresh tissue is generally preferred over formalin-fixed, paraffin-embedded tissue, but either can be tested.

Submit only 1 of the following specimens:**Preferred:****Specimen Type:** Fresh tissue or biopsy**Sources:** Normally sterile tissue such as bone, lymph node, joint, heart valve, brain, viscera, organ, lung, prostate**Container/Tube:** Sterile container**Specimen Volume:** Entire collection or 5 mm(3)-approximately the size of a pencil eraser**Collection Instructions:**

1. Collect fresh tissue specimen.
2. Submit tissue only, do not add fluid (eg, saline, broth, formalin, formaldehyde, acetone) to tissue. Body fluid accompanying tissue is acceptable.
3. Freeze specimen.

Specimen Stability Information: Frozen (preferred) 21 days/Refrigerated 21 days**Acceptable:****Preferred:** Paraffin-embedded tissue block**Supplies:** Tissue Block Container (T553)**Specimen Type:** Formalin-fixed, paraffin-embedded (FFPE) tissue block**Source:** Normally sterile or deep tissues such as bone, lymph node, joint, heart valve, brain, viscera, organ, lung, prostate**Container/Tube:** Tissue block**Collection Instructions:** Submit a formalin-fixed, paraffin-embedded tissue block to be cut and returned.**Specimen Stability Information:** Ambient (preferred)/Refrigerated**Acceptable:** Paraffin-embedded tissue block**Specimen Type:** Section (scrolls) of FFPE tissue block

Source: Normally sterile or deep tissues such as bone, lymph node, joint, heart valve, brain, viscera, organ, lung, prostate

Container/Tube: Sterile container for each individual cut section (scroll)

Collection Instructions: Perform microtomy and prepare five separate 10-micron sections. **Each section (scroll) must be placed in a separate sterile container for submission.**

Specimen Stability Information: Ambient (preferred)/Refrigerated

Specimen Type: Fluid

Sources: Normally sterile body fluids such as vitreous humor, pleural, abdominal, peritoneal, ascites, pericardial, pelvic, prostatic

Container/Tube: Screw-capped, sterile container

Specimen Volume: 0.5 mL

Collection Instructions:

1. Collect fresh fluid specimen.
2. Freeze specimen.

Specimen Stability Information: Frozen (preferred) 21 days/Refrigerated 21 days

Specimen Type: Spinal fluid

Container/Tube: Screw-capped, sterile container

Specimen Volume: 0.5 mL

Collection Instructions:

1. Collect fresh spinal fluid (CSF) specimen using sterile technique.
2. Submit specimen from collection vial 2 or higher, specimens in vial 1 are not acceptable.
3. Indicate on the label which vial is being submitted.
4. CSF collected by lumbar puncture is preferred. CSF collected via shunt and ventricular fluid are also acceptable; label tube with applicable collection information if submitting nonlumbar puncture collected CSF.

Specimen Stability Information: Frozen (preferred) 21 days/Refrigerated 21 days

Specimen Type: Synovial fluid

Container/Tube:

Preferred: Red top or sterile container

Acceptable: Lavender top (EDTA), pink top (EDTA), royal blue top (EDTA), or sterile vial containing EDTA-derived aliquot

Specimen Volume: 0.5 mL

Collection Instructions: Send specimen in original tube (preferred).

Specimen Stability Information: Frozen (preferred) 21 days/Refrigerated 21 days

Forms

If not ordering electronically, complete, print, and send a [Microbiology Test Request](#) (T244) with the specimen.

Specimen Minimum Volume

Fluid: 0.2 mL; Fresh tissue or biopsy: 5 mm(3); Paraffin-embedded tissue block: two 10-micron sections

Reject Due To

Tissue received	Reject
-----------------	--------

in any exogenous fluid (eg, saline, broth, formalin, formaldehyde, acetone)	
Specimen received in anaerobe vial	Reject
Wrapping (gauze, drapes, etc)	Reject
Blood Culture bottles (Bactec FX or BacT/ALERT bottles)	Reject
Bone marrow	Reject
Decalcified bone	Reject
Slides	Reject
Skin biopsy	Reject
Colon biopsy	Reject
Formalin-fixed paraffin-embedded body fluid	Reject

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Varies	Varies		

Clinical & Interpretive

Clinical Information

Cultures from patients with suspected bacterial infection involving normally sterile sites may fail to provide bacterial (including mycobacterial) growth for identification due to the presence of fastidious or slow-growing bacteria or because of antecedent antimicrobial chemotherapy. Polymerase chain reaction amplification of a portion of the 16S ribosomal RNA (rRNA) gene followed by sequencing of the amplified product can be used to detect bacterial (including mycobacterial) nucleic acids in such situations, enabling a diagnosis. Ideal specimens are those in which bacteria

(including mycobacteria) are visualized by microscopy. Heart valves from patients with endocarditis with positive stains are especially suitable.

Reference Values

No bacterial DNA detected

Interpretation

A positive broad-range polymerase chain reaction (PCR)/next-generation sequencing result indicates that bacterial nucleic acid of the specified organism was detected, which may be due to bacterial infection or environmental or contaminating nucleic acids in the specimen.

A negative broad-range PCR/next-generation sequencing result indicates the absence of detectable bacterial (including mycobacterial) nucleic acids in the specimen but does not rule out false-negative results that may occur due to sampling error, sequence variability underlying the primers, the presence of bacterial nucleic acids in quantities below the limit of detection of the assay, or inhibition of PCR. If PCR testing appears to be negative but there is evidence of PCR inhibition, testing will be repeated. If inhibition is again detected, the result will be reported as "PCR inhibition present."

Cautions

This test does not detect nonbacterial organisms (eg, viruses, fungi, helminths, protozoa) but does detect mycobacteria.

False-positive results are theoretically possible if patient specimens or collection containers are contaminated with bacterial nucleic acids either from the environment or from patient microbiota (eg, skin microbiota contamination).

This test is validated for normally sterile sources.

In extenuating circumstances, performance of next-generation sequencing may be associated with an extended turnaround time, approaching, or possibly exceeding, the published maximum report available time (28 days). This typically happens if repeat testing is needed, information about the specimen is being sought, or orthogonal testing is being performed.

Supportive Data

One hundred thirty positive patient specimens were available for accuracy studies and correlated with results of culture, organism-specific polymerase chain reaction (PCR), or previous broad-range bacterial PCR and sequencing. In addition, 63 negative samples from previous Sanger sequence-based testing were used in verification. All samples were tested with next-generation sequencing (NGS). Using criteria established during validation, analytical sensitivity of the assay is 99% and specificity is 97%. Some samples were spiked with gram-negative or gram-positive bacteria due to the scarcity of clinically positive samples. Testing demonstrated 100% correlation with expected results from spiked material.

The limit of detection is less than 65 colony forming units per PCR reaction for all sources as determined by spiking *Streptococcus gallolyticus* and *Escherichia coli* into PCR-negative fresh tissue, synovial fluid, formalin-fixed, paraffin-embedded tissue, sonicate fluid, body fluid, and cerebrospinal fluid.

Specificity was tested using a panel of 10 nucleic acid extracts from viral, fungal, and parasitic organisms. No cross-reactivity to these organisms was observed.

Inclusivity studies were performed by amplifying 42 genomic DNA samples representing diverse types of bacteria (including mycobacteria) expected to be present in the specimen types acceptable for this assay. All bacteria and mycobacteria were detected and correctly identified by NGS.

An additional study of 15 specimens previously characterized only as polybacterial revealed the ability of NGS to detect and differentiate multiple bacteria for reporting.

Clinical Reference

1. Virk A, Pritt B, Patel R, et al. *Mycobacterium lepromatosis* lepromatous leprosy in US citizen who traveled to disease-endemic areas. *Emerg Infect Dis*. 2017;23(11):1864-1866. doi:10.3201/eid2311.171104
2. Liesman RM, Pritt BS, Maleszewski JJ, Patel R. Laboratory diagnosis of infective endocarditis. *J Clin Microbiol*. 2017;55(9):2599-2608. doi:10.1128/JCM.00635-17
3. Ramakrishna JM, Libertin CR, Yang JN, Diaz MA, Nengue AL, Patel R. 16S rRNA gene PCR/sequencing of cerebrospinal fluid in the diagnosis of post-operative meningitis. *Access Microbiol*. 2020;2(2):acmii.0.000100
4. Alvarez Otero J, Mandrekar J, Wolf MJ, et al. Pleural space infection microbiology as assessed using a clinical sequencing-based assay: *Fusobacterium nucleatum* group, *Streptococcus intermedius*, and other oral normal microbiota are the most common bacteria identified in community-acquired pleural space infections. *J Clin Microbiol*. 2024;62(12):e0069424. doi:10.1128/jcm.00694-24
5. Azad MA, Wolf MJ, Strasburg AP, et al. Comparison of the BioFire Joint Infection Panel to 16S ribosomal RNA gene-based targeted metagenomic sequencing for testing synovial fluid from patients with knee arthroplasty failure. *J Clin Microbiol*. 2022;60(12):e0112622. doi:10.1128/jcm.01126-22
6. Fowler VG, Durack DT, Selton-Suty C, et al. The 2023 Duke-International Society for Cardiovascular Infectious Diseases criteria for infective endocarditis: Updating the modified Duke criteria. *Clin Infect Dis*. 2023;77(4):518-526. doi:10.1093/cid/ciad271
7. Flurin L, Wolf MJ, Mutchler MM, Daniels ML, Wengenack NL, Patel R. Targeted metagenomic sequencing-based approach applied to 2146 tissue and body fluid samples in routine clinical practice. *Clin Infect Dis*. 2022;75(10):1800-1808. doi:10.1093/cid/ciac247
8. Hong HL, Flurin L, Greenwood-Quaintance KE, et al. 16S rRNA gene PCR/sequencing of heart valves for diagnosis of infective endocarditis in routine clinical practice. *J Clin Microbiol*. 2023;61(8):e0034123. doi:10.1128/jcm.00341-23

Performance

Method Description

This test utilizes specimen processing, DNA extraction, and polymerase chain reaction (PCR) of a highly variable fragment of the 16S ribosomal RNA (rRNA) gene. Variability of the targeted V1-V3 region allows for taxonomically specific reporting. If positive by PCR based on signal strength, the amplified DNA is sequenced to obtain identification of the source organism. If PCR is negative, no next-generation sequencing (NGS) is performed. PCR inhibition is detected with a second PCR reaction and amplification is performed on a LightCycler. Quality filtering is performed for NGS. Positive and negative controls are used throughout all processes to ensure assay performance. Sequence quality (specimen score) and data analysis for organism identification is accomplished with Pathogenomix RipSeq software.(Unpublished Mayo method)

PDF Report

No

Day(s) Performed

Monday through Friday

Report Available

14 to 28 days

Specimen Retention Time

1 week

Performing Laboratory Location

Mayo Clinic Laboratories - Rochester Main Campus

Fees & Codes

Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

- 87801-Broad Range Bacterial PCR and Sequencing
- 87798-Specimen Identification by PCR (if appropriate)
- 87798-Ident by Next Generation Sequencing (if appropriate)
- 87483-Meningitis Encephalitis Panel, PCR (if appropriate)
- 87999-Joint Infection Panel, PCR, Synovial Fluid (if appropriate)

LOINC® Information

Test ID	Test Order Name	Order LOINC® Value
BRBPS	Broad Range Bacteria PCR+Sequencing	76575-0

Result ID	Test Result Name	Result LOINC® Value
BRBPS	Broad Range Bacteria PCR+Sequencing	76575-0